NCT00636636View on ClinicalTrials.gov

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

PHASE3CompletedINTERVENTIONAL
Enrollment

452

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

September 30, 2009

Conditions
Neuralgia,Postherpetic
Interventions
DRUG

Gabapentin Extended Release tablets

Once-Daily; 300 mg and 600 mg tablets

DRUG

Placebo

Once daily; 300 mg and 600 mg tablets

Trial Locations (39)

Unknown

Birmingham

Tuscaloosa

Phoenix

Little Rock

Lancaster

Los Angeles

Pismo Beach

Colorado Springs

Pueblo

Daytona Beach

Naples

New Port Richey

Orlando

Tampa

Marietta

Honolulu

Elk Grove Village

Shreveport

West Yarmouth

Ann Arbor

Florissant

Jefferson City

Albuquerque

High Point

Bismarck

Fargo

Canton

Cincinnati

Kettering

Warwick

Murrells Inlet

Pelzer

Tullahoma

Austin

Longview

Spokane

Buenos Aires

All Over Russia

Saint Petersburg

Sponsors

Lead Sponsor

Depomed
All Listed Sponsors
lead

Depomed

INDUSTRY

NCT00636636 - Safety and Efficacy of Gabapentin in Postherpetic Neuralgia | Biotech Hunter | Biotech Hunter